Silver Book

Silver Book Fact

Identifying individuals at high risk for developing AFib

Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.

Schnabel, RB, LM Sullivan, D Levy, MJ Pencina, JM Massaro, RB Dâ??Agostino, C Newton-Cheh, JF Yamamoto, JW Magnani, TM Tadros, WB Kannel, TJ Wang, PT Ellinor, PA Wolf, RS Vasan, and EJ Benjamin. Development of a Risk Score for Atrial Fibrillation (Framingham Heart Study): A community-based cohort study. Lancet. 2009; 373(9665): 739-45. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2809%2960443-8/abstract

Reference

Title
Development of a Risk Score for Atrial Fibrillation (Framingham Heart Study): A community-based cohort study
Publication
Lancet
Publication Date
2009
Authors
Schnabel, RB, LM Sullivan, D Levy, MJ Pencina, JM Massaro, RB Dâ??Agostino, C Newton-Cheh, JF Yamamoto, JW Magnani, TM Tadros, WB Kannel, TJ Wang, PT Ellinor, PA Wolf, RS Vasan, and EJ Benjamin
Volume & Issue
Volume 373, Issue 9665
Pages
739-45
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Effectiveness of pacemaker/defibrillators to control AFib
    Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.  
  • Catheter ablation reduces risk of stroke and death among AFib patients
    Atrial fibrillation patients who underwent catheter ablation had a reduced risk of stroke and death—2.2% of those who had ablation experienced stroke versus 4.7% on medications alone, and 6% died from…  
  • Adjusted-dose warfarin reduced stroke risk in AFib patients
    Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.